IntriCon Corporation (NASDAQ: IIN), a designer,
developer, manufacturer and distributor of body-worn medical
devices, today announced financial results for its second quarter
ended June 30, 2010.
For the second quarter, the company reported net sales of $14.9
million, an increase of 16.6 percent from net sales of $12.8
million for the prior-year period. Net income in the 2010
second-quarter was $269,000, or $0.05 per diluted share, versus a
net loss of $598,000, or $0.11 per diluted share, for the
prior-year period.
IntriCon reported 2010 second-quarter income from continuing
operations—which consists of the company’s body-worn device
business (medical, hearing health and professional audio
communications)—of $404,000, or $0.07 per diluted share.
Second-quarter results from discontinued operations in 2010 were a
net loss of $135,000, including the $35,000 gain on the sale of RTI
Electronics, or $0.02 per diluted share.
On May 28, 2010, the company completed the previously announced
divestiture of its non-core electronics business, Anaheim,
Calif.-based RTI Electronics, Inc. IntriCon sold substantially all
of the assets of the business to an affiliate of Shackleton Equity
Partners, a Los Angeles-based private equity group. The company
received $850,000 in cash and reported a $35,000 gain on the sale
of RTI Electronics in the second quarter.
“We’re pleased with our second-quarter performance—delivering
both year-over-year and sequential top- and bottom-line gains,”
said Mark S. Gorder, president and chief executive officer of
IntriCon. “Moreover, the sale of RTI Electronics allows us to focus
on our core body-worn business.
“Medical continued to post record revenues, rising 19 percent
from the previous year. Once again, medical gains were the result
of continued sales of wireless glucose monitors and the addition of
sales from our proprietary cardiac diagnostic monitoring devices,
or CDMs. Currently, CDM sales consist of digital holter monitors
designed for continuous electrocardiograph (ECG) data recording.
Additionally, the wireless glucose monitors we manufacture for a
large medical OEM are first- and second-generation devices. We are
actively involved with this customer for future development of
next-generation wireless glucose monitors.”
Professional audio communications rose 50 percent from the prior
year, primarily through organic growth, sales of headset devices to
the installed sound market and communication devices to security
agencies. Fueling this business is increasing marketplace demand
for smaller and more durable devices that perform well in noisy or
hazardous environments.
Hearing health revenues remained relatively flat compared to the
2009 second quarter. Growth was hampered by sustained sluggishness
in consumer spending on hearing aids.
Said Gorder, “In the first quarter, we introduced the Scenic™
and Overtus™ DSP amplifiers. While these technology-leading
products are anticipated to have a positive impact in late 2010,
they are still gaining traction with customers. As the hearing
health market rebounds, we believe these products will be the
drivers of future hearing health growth.”
Gross profit in the 2010 second quarter was 27.0 percent, up
significantly from 21.0 percent in the year-ago period—and also up
from 2010 first-quarter gross profit of 25.3 percent. The primary
drivers of the gains were higher sales volumes and the impact of
various margin enhancement programs. IntriCon continues to
implement gross profit improvement initiatives, including
production transfers to lower-cost manufacturing facilities and the
rollout of lean manufacturing programs.
For the 2010 six-month period, IntriCon reported net sales of
$29.5 million and net income of $287,000, or $0.05 per diluted
share. This was up from 2009 net sales of $24.7 million and a net
loss of $1.6 million, or $(0.30) per diluted share. Six-month 2010
net income from the company’s core business was $581,000, or $0.11
per share, with a non-core net loss of $294,000 (including the
$35,000 gain on sale of RTI Electronics), or a loss of $0.06 per
share. For the six months ended June 30, 2009, core business net
loss was $1.2 million, or $0.23 per share; non-core business net
loss was $357,000, or $0.07 per share.
During the first six months of 2010, IntriCon paid down bank
debt from $8.4 million at 2009 year end to $7.1 million. This was
driven by improved financial performance, tight cash management and
the sale of RTI Electronics.
Business UpdateIn the medical arena, the company
continues to make progress with its new Centauri cardiac diagnostic
monitoring device. Centauri is a next-generation wireless
outpatient monitoring device that uses a proven automatic
arrhythmia detection algorithm. Said Gorder, “We anticipate 2010
fourth quarter FDA approval and we will begin selling the Centauri
product right afterward.”
In April, IntriCon unveiled its Overtus DSP amplifier at
AudiologyNOW!—the annual convention of the American Academy of
Audiology. Overtus DSP is designed to optimize open in-the-canal
(ITC) type fittings and features an advanced adaptive feedback
canceller and an acoustic switch that eliminates the need for a
mechanical switch and allows for further miniaturization. Overtus
is expected to be released at the end of the third quarter and is
anticipated to have a modest sales impact throughout the remainder
of the 2010 fiscal year.
The company’s new PhysioLink™ wireless technology, which also
premiered at AudiologyNOW!, is currently being incorporated into
IntriCon products in the medical, hearing health and professional
audio communication markets. PhysioLink consists of a 2.4GHz radio,
communications protocol processing and miniature antenna, packaged
into a compact module suitable for ear-worn and body-worn
applications of audio and data streaming over distances of up to
five meters.
Said Gorder, “PhysioLink has the potential to span all of our
businesses including hearing aids, professional audio products,
situational listening devices, cardiac diagnostic monitors and
other biotelemetry devices. This proprietary technology allows for
wireless data links, which consume significantly less power than
Bluetooth radios, resulting in more compact devices.”
The company continues development of its situational listening
device (SLD) product line. SLDs help hearing-impaired people in
noisy environments, and allow them to listen to television and
music by direct wireless connection. SLDs supplement conventional
hearing aids that don’t handle noisy situations well. IntriCon
anticipates a 2011 first-quarter launch for its line of SLDs.
Concluded Gorder, “We spent a large part of 2009 positioning
IntriCon to better support our medical, hearing health and
professional audio communications customers with new devices. In
2010, our efforts are starting to pay off and now more than ever,
we’re able to fully focus our resources and capital on our core
strengths: making body-worn devices smaller, more effective and
better connected than ever before. We’re excited about the future
and remain cautiously optimistic about our ability to continue to
deliver growth.”
Conference Call TodayAs previously announced, the company
will hold an investment community conference call today, Tuesday,
July 27, 2010, beginning at 4:00 p.m. CT. Mark Gorder, president
and chief executive officer, and Scott Longval, chief financial
officer, will review second-quarter performance and discuss the
company’s strategies. To join the conference call, dial:
1-800-762-8908 (international 1-480-629-9773) and provide the
conference identification number 4330745 to the operator.
A replay of the conference call will be available one hour after
the call ends through 11:59 p.m. CT on Tuesday, August 3, 2010. To
access the replay, dial 1-800-406-7325 (international
1-303-590-3030) and enter access code: 4330745.
About IntriCon CorporationHeadquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures
miniature and micro-miniature body-worn medical products. The
company is focused on three key markets: medical, hearing health,
and professional audio and communications. IntriCon has facilities
in the United States, Asia and Europe. The company’s common stock
trades under the symbol “IIN” on the NASDAQ Global Market. For more
information about IntriCon, visit www.intricon.com.
Forward-Looking StatementsStatements made in this release
and in IntriCon’s other public filings and releases that are not
historical facts or that include forward-looking terminology such
as “may”, “will”, “believe”, “anticipate,” “expect”, “should”,
“optimistic” or “continue” or the negative thereof or other
variations thereon are “forward-looking statements” within the
meaning of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, without limitation, statements
concerning prospects in the miniature body-worn device arena, new
products, strategic alliances, future growth and expansion, market
fundamentals, future financial condition and performance, prospects
and the positioning of IntriCon to compete in chosen markets and
the Company’s planned investments in research and development.
These forward-looking statements may be affected by known and
unknown risks, uncertainties and other factors that are beyond
IntriCon’s control, and may cause IntriCon’s actual results,
performance or achievements to differ materially from the results,
performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and factors
include, without limitation, risks related to the current economic
crisis, the risk that IntriCon may not be able to achieve its
long-term strategy, weakening demand for products of the company
due to general economic conditions, risks related to the company’s
strategic alliances and joint venture, possible non-performance of
developing the Centauri, Scenic, Overtus, wireless glucose monitor
and situational listening device products and other technological
products, the volume and timing of orders received by the company,
changes in the mix of products sold, competitive pricing pressures,
the cost and availability of electronic components and commodities
for the company’s products, ability to create and market products
in a timely manner, competition by competitors with more resources
than the company, foreign currency risks arising from the company’s
foreign operations, ability to satisfy and maintain compliance with
the covenants under the company’s loan facility, the costs and
risks associated with research and development investments and
other risks detailed from time to time in the company’s filings
with the Securities and Exchange Commission, including the Annual
Report on Form 10-K for the year ended December 31, 2009. The
company disclaims any intent or obligation to publicly update or
revise any forward-looking statements, regardless of whether new
information becomes available, future developments occur or
otherwise.
IntriCon Corporation Consolidated
Condensed Statements of Operations (in thousands, except per share
data) Three Months Ended Six Months Ended June 30,
June 30, June 30, June 30, 2010 2009 2010 2009
(Unaudited) (Unaudited)
(Unaudited) (Unaudited) Sales, net
$ 14,934 $ 12,811 $ 29,488 $ 24,655 Cost of sales
10,903 10,118
21,781 19,786 Gross
profit 4,031 2,693 7,707 4,869 Operating expenses: Selling expense
835 710 1,622 1,329 General and administrative expense (a) 1,493
1,400 2,937 2,779 Research and development expense
1,105 787
2,224 1,667 Total
operating expenses
3,433
2,897 6,783
5,775 Operating income (loss) 598 (204 ) 924
(906 ) Interest expense (172 ) (118 ) (342 ) (243 ) Equity
in loss of partnerships -- (114 ) (12 ) (201 ) Other income, net
42 25
86 82 Income (loss)
from continuing operations before income taxes and discontinued
operations 468 (411 ) 656 (1,268 ) Income tax expense
(benefit)
64 12
75 (38
) Income (loss) before discontinued operations 404
(423 ) 581 (1,230 ) Loss from discontinued operations, net
of income taxes (170 ) (175 ) (329 ) (357 ) Gain on sale of
discontinued operations
35
-- 35
-- Net income (loss)
$
269 $ (598
) $ 287
$ (1,587 ) Basic
income (loss) per share:
Continuing operations $ 0.07 $ (0.08 ) $ 0.11 $ (0.23 )
Discontinued operations
$ (0.02
) $ (0.03 )
$ (0.06 ) $
(0.07 ) Net income (loss)
$
0.05 $ (0.11
) $ 0.05
$ (0.30 ) Diluted
income (loss) per share: Continuing operations $ 0.07 $ (0.08 ) $
0.11 $ (0.23 ) Discontinued operations
$
(0.02 ) $ (0.03
) $ (0.06 )
$ (0.07 ) Net income (loss)
$ 0.05 $
(0.11 ) $ 0.05
$ (0.30 )
Average shares outstanding: Basic 5,476 5,354 5,474 5,348 Diluted
5,614 5,354 5,496 5,348
(a) General and administrative expenses includes $121 and $239
of non-cash stock compensation expense for the three and six months
ended June 30, 2010 and $134 and $272 for the 2009 comparable
periods.
IntriCon Corporation Consolidated Condensed
Balance Sheets (in thousands) June 30, December 31, 2010
2009 (Unaudited) Current assets: Cash $ 563 $ 385
Restricted cash 413 406 Accounts receivable, less allowance for
doubtful accounts of $246 at June 30, 2010 and $226 at December 31,
2009 7,527 7,084 Inventories 8,457 8,221 Other current assets 450
815 Current assets of discontinued operations
-- 1,204 Total
current assets 17,410 18,115 Machinery and equipment 36,242
35,516 Less: Accumulated depreciation
29,740
28,725 Net machinery and
equipment 6,502 6,791 Goodwill 9,709 9,717 Investment in
partnerships 1,225 1,237 Other assets of discontinued operations --
142 Other assets, net
1,368
1,361 Total assets
$
36,214 $ 37,363
Current liabilities: Checks written in excess of cash
$ 185 $ 102 Current maturities of long-term debt 1,835 1,709
Accounts payable 3,502 3,637 Deferred gain 110 110 Partnership
payable 260 260 Liabilities of discontinued operations -- 926 Other
accrued liabilities
3,688
2,867 Total current liabilities 9,580 9,611
Long-term debt, less current maturities 6,274 7,730 Other
postretirement benefit obligations 716 756 Long-term partnership
payable 500 500 Deferred income taxes 147 129 Accrued pension
liabilities 457 543 Deferred gain
550
605 Total liabilities 18,224 19,874
Commitments and contingencies -- -- Shareholders’
equity: Common shares, $1.00 par value per share; 20,000 shares
authorized; 5,995 and 5,986 shares issued; 5,480 and 5,470 shares
outstanding at June 30, 2010 and December 31, 2009, respectively.
5,996 5,986 Additional paid-in capital 15,257 14,987 Retained
deficit (1,718 ) (2,005 ) Accumulated other comprehensive loss (280
) (214 ) Less: 516 common shares held in treasury, at cost
(1,265 ) (1,265
) Total shareholders' equity 17,990 17,489 Total
liabilities and shareholders’ equity
$
36,214 $ 37,363
Intricon (NASDAQ:IIN)
Historical Stock Chart
From Apr 2024 to May 2024
Intricon (NASDAQ:IIN)
Historical Stock Chart
From May 2023 to May 2024